Kelly A. Soltysiak

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Christopher B. Benton et al. · Blood Advances · 2020 · 132 citations · Full text

Life Sciences, Genetics, Hematology +17

Impact of the variant allele frequency of <i>ASXL1</i>, <i>DNMT3A</i>, <i>JAK2</i>, <i>TET2</i>, <i>TP53</i>, and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia

Koji Sasaki, Rashmi Kanagal‐Shamanna, Guillermo Montalban‐Bravo et al. · Cancer · 2019 · 99 citations

Life Sciences, Genetics, Molecular Genetics +16

Selective Allosteric Enhancement of Agonist Binding and Function at Human A3 Adenosine Receptors by a Series of Imidazoquinoline Derivatives

Zhan‐Guo Gao, Seong‐Gon Kim, Kelly A. Soltysiak et al. · Molecular Pharmacology · 2002 · 68 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

Kelly S. Chien, Kunhwa Kim, Graciela M. Nogueras‐González et al. · British Journal of Haematology · 2021 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor necrosis factor α-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors

Seong G. Kim, Kelly A. Soltysiak, Zhan‐Guo Gao et al. · Biochemical Pharmacology · 2003 · 55 citations

Life Sciences, Neurobiology, Neuroscience +11